You are here

New Formulations of Omeprazole Delayed-Release Capsules Approved by FDA

PITTSBURGH, PA – June 2, 2003 – Mylan Laboratories Inc. (NYSE: MYL) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-release Capsules, 10 mg and 20 mg strengths and tentative approval for the 40 mg strength.

Omeprazole Delayed-release Capsules is the generic version of AstraZeneca LP’s Prilosec®.

More Headlines

However, patent dispute will delay one launch
Some experts still opposed to “right to try” treatments
Approval acquired through tropical disease priority review voucher program
FDA questioning the pharmacokinetics of psoriasis lotion Duobrii
Therapy approved for adults and children with refractory PMBCL or who have relapsed after two or more prior lines of therapy
Latest failure brings amyloid hypothesis into question
Guidance published on how to best design coverage for treatment of the smallest, most vulnerable victims of the opioid crisis
Agency plans to respond after receipt of letter of concern
Continuous nerve stimulation helps to alleviate withdrawal symptoms